Skip to main content
      It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
      Understanding Comorbidities in RMD

      People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of

      Dr. John Cush RheumNow

      6 days 5 hours ago
      Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
      #OP0159 #EULAR2026
      Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychologic

      Mrinalini Dey DrMiniDey

      1 week ago
      #OP0159 #EULAR2026 Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow https://t.co/qMQbkiMCwX
      Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, gr

      Jiha Lee JihaRheum

      1 week ago
      Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, grip strength, but aging's effect on function similar in RA vs controls. Geriatric syndromes like sarcopenia may matter more than RA @RheumNow #EULAR2026 POS0360
      Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs?

      RISE registry
      Retrospective
      N=60,206

      Tirzepati

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs? RISE registry Retrospective N=60,206 Tirzepatide: lost 8% Semaglutide: list 6% At 12 months PsA had the highest usage OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr
      Machine learning identifies a “vulnerable” phenotype in older RA patients n=275

      -51% “vulnerable”
      -Worse grip s

      Aurelie Najm AurelieRheumo

      1 week ago
      Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR
      Failure to achieve early remission RA asso w/ non-inflammatory pain

      NORD-STAR 526 early RA pts)
      no remission at 24 wks

      Aurelie Najm AurelieRheumo

      1 week ago
      Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw
      What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients a

      Jiha Lee JihaRheum

      1 week 1 day ago
      What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX
      Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.
      What does remission look like for people living with PsA?

      Much more than the absence of swollen joints

      Absence of pain

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      What does remission look like for people living with PsA? Much more than the absence of swollen joints Absence of pain Skin management Ability to resume daily activities Sustained over time A definition not always reflected in our disease activity scores #POS0294 #EULAR2026 https://t.co/VCnMGAOVYm
      PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging
      #EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor phy

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 2 days ago
      #EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN
      🔮 Can polygenic risk scores predict PsA timing in psoriasis?

      Another GWAS study (n=703) says YES!
      70-SNP model ach

      Nelly ZIADE 🍀 Nellziade

      1 week 2 days ago
      🔮 Can polygenic risk scores predict PsA timing in psoriasis? Another GWAS study (n=703) says YES! 70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years #POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A
      @RheumNow HOT #Obesity session (7)

      📢A call for action
      Current RMD treatments ignore obesity:
      They all target immune

      Nelly ZIADE 🍀 Nellziade

      1 week 2 days ago
      @RheumNow HOT #Obesity session (7) 📢A call for action Current RMD treatments ignore obesity: They all target immune response but miss the metabolic-inflammatory loop Breaking that cycle may be the missing piece Obesity must be part of every rheumatology plan #EULAR2026 @rheumnow
      Treatment for #lupus #brain #fog?!

      #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #

      Janet Pope Janetbirdope

      1 week 2 days ago
      Treatment for #lupus #brain #fog?! #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR #memantine N=19 v #PBO N=25 showed more improvemt #EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7
      ×